Chimeric Antigen Receptor News and Research

RSS

Asimov launches LV Edge Packaging System to optimize lentivirus production

New off-the-shelf system reduces the cost and risk of lentiviral (LV) production for cell and gene therapy developers.

From Asimov 29 Jan 2024

Dr. Chao Ma: Pioneering 'Leukemia-on-a-Chip' for CAR T Cell Therapy at SLAS 2024

NewsMedical speaks with Chao Ma, Ph.D. a Research Assistant Professor at New York University Tandon School of Engineering, ahead of his presentation at SLAS 2024.

From Society for Laboratory Automation and Screening (SLAS) 29 Jan 2024

Revolutionary CAR T-cell therapy shows promise in reversing age-related metabolic dysfunction

study evaluates senolytic CAR T-cell therapy targeting uPAR-positive cells in aged mice, showing its effectiveness in mitigating age-related metabolic dysfunction and offering a potential long-lasting treatment for aging-associated conditions.

28 Jan 2024

T cells can be reprogrammed to fight aging

The fountain of youth has eluded explorers for ages. It turns out the magic anti-aging elixir might have been inside us all along.

24 Jan 2024

New workflow identifies shared cancer targets, advancing immunotherapy

Researchers developed the Splicing Neo Antigen Finder (SNAF) workflow, integrating deep learning to identify shared immunogenic neoantigens in cancers, offering new targets for cancer immunotherapy, particularly in melanoma and ovarian cancer.

23 Jan 2024

Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Researchers from The University of Texas MD Anderson Cancer Center reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.

18 Jan 2024

Decoding blood cancer secrets to optimize CAR T therapy

Chimeric antigen receptor T-cell therapy, or CAR T, has dramatically improved the treatment of certain blood cancers. Initially approved for patients who had failed multiple lines of therapy, clinical trials have shown CAR T can be used as an earlier treatment option.

17 Jan 2024

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third-generation anti-CD19 chimeric antigen receptor (CAR) T-cell therapy to be presented at the American Society of Hematology (ASH) Annual Meeting in San Diego on 11 December, 3pm.

11 Dec 2023

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

A study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that CAR-T immunotherapy remains a viable option for patients who have lymphoma that goes into remission before the cell therapy begins.

11 Dec 2023

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

11 Dec 2023

CHOP researchers unlock 3D structure of crucial protein for cancer therapy

Chimeric Antigen Receptors (CARs) have opened up an exciting new field of therapeutic advancements for rare and difficult-to-treat cancers, as they have the ability to deliver targeted therapies that can kill tumor cells.

1 Dec 2023

New approach enhances CAR T-cell therapy for solid tumors

Immunotherapy using modified chimeric antigen receptor (CAR) T cells has greatly improved survival rates for pediatric patients with relapsed and recurrent leukemia.

30 Nov 2023

Study finds diet-derived trans-vaccenic acid boosts anti-tumor immunity

Dietary components that impact anti-tumor immunity.

28 Nov 2023

Researchers develop $1 cancer treatment using engineered bacteria

What if a single one-dollar dose could cure cancer?

27 Nov 2023

Novel method can detect contaminants in T-cell cultures within 24 hours

Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT's research enterprise in Singapore, in collaboration with Singapore Centre for Environmental Life Sciences Engineering (SCELSE) and Massachusetts Institute of Technology (MIT), have developed a novel method capable of identifying contaminants in T-cell cultures within 24 hours.

27 Nov 2023

St. Jude scientists discover potential CAR T cell therapy target for brain and solid tumors

Findings from St. Jude Children's Research Hospital are moving the field of cancer immunotherapy one step closer to treating brain and solid tumors.

21 Nov 2023

Scientists uncover key to enhancing cancer-killing T cells

T cells are the key immune system component involved in killing cancer. Tumors produce signals that turn off these T cells, partially by forcing them to progressively differentiate (mature) into a hypofunctional state known as exhaustion.

21 Nov 2023

New approach to CAR T cell therapy may extend treatment effectiveness

CAR T cell therapy, a powerful type of immunotherapy, has begun to revolutionize cancer treatment. Pioneered at Memorial Sloan Kettering Cancer Center (MSK), the therapy involves engineering a patient's T cells so they recognize and attack cancer cells.

14 Nov 2023

Next-generation ovarian cancer therapy: Engineered Vδ2 T cells show promise in preclinical trials

A prospective path for allogeneic cellular immunotherapies.

13 Nov 2023

Gamma delta T cells engineered to be more potent and long-lasting against cancer

UCLA scientists have developed a new method to engineer more powerful immune cells that can potentially be used for "off-the-shelf" cell therapy to treat challenging cancers.

8 Nov 2023

Chimeric Antigen Receptor News and Research

Asimov launches LV Edge Packaging System to optimize lentivirus production

Dr. Chao Ma: Pioneering 'Leukemia-on-a-Chip' for CAR T Cell Therapy at SLAS 2024

Revolutionary CAR T-cell therapy shows promise in reversing age-related metabolic dysfunction

T cells can be reprogrammed to fight aging

New workflow identifies shared cancer targets, advancing immunotherapy

Cord blood-derived CAR NK cell therapy targeting CD19 shows promise for treating patients with B-cell malignancies

Decoding blood cancer secrets to optimize CAR T therapy

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

CAR-T cell therapy remains viable for patients in lymphoma remission, study finds

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

CHOP researchers unlock 3D structure of crucial protein for cancer therapy

New approach enhances CAR T-cell therapy for solid tumors

Study finds diet-derived trans-vaccenic acid boosts anti-tumor immunity

Researchers develop $1 cancer treatment using engineered bacteria

Novel method can detect contaminants in T-cell cultures within 24 hours

St. Jude scientists discover potential CAR T cell therapy target for brain and solid tumors

Scientists uncover key to enhancing cancer-killing T cells

New approach to CAR T cell therapy may extend treatment effectiveness

Next-generation ovarian cancer therapy: Engineered Vδ2 T cells show promise in preclinical trials

Gamma delta T cells engineered to be more potent and long-lasting against cancer

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News